MUSCULOSKELETAL (MSK) INFECTION

Algorithm 1. Musculoskeletal Infection: Diagnostic

**Patient arrives with clinical suspicion for acute musculoskeletal (MSK) infection based on history and physical exam**

- Obtain two blood cultures immediately
- Ceftaroline (broad coverage for MSSA, MRSA, and gram negatives)
- +/− Clindamycin if concern for toxin-mediated illness
- Emergently Consult Orthopedic Surgery and Infectious Diseases
- Timing of additional imaging (MRI) dependent on patient status
- Operative source control as soon as patient stability allows, particularly important for toxic shock
- Refer to Sepsis Pathway for additional emergent interventions
- Proceed to Algorithm 2. Musculoskeletal Infection: Management

**Initial work-up (all patients):**

- 2-view x-rays of area
- CBC with differential
- ESR
- CRP
- Blood cultures x2

**Optional (patient ill-appearing):**

- Lactate, CMP, INR

**Are any of the following true:**

1. X-ray concerning for infection
2. Fever greater than 38.5ºC
3. Abnormal labs:
   a. White blood cell count (greater than 12K or less than 5K)
   b. ESR (greater than 40)
   c. CRP (greater than 2 mg/dL or 20mg/L)

**Suspected septic knee:**

- ED aspiration for synovial cell count, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5 years) and bacterial culture

- If suspected bacterial (greater than 50K cell count, + gram stain, clinically consistent), proceed with MSK infection pathway
- Consider Lyme disease if travel to endemic area, send serologic studies from blood and consult ID/Ortho if needed
- If measuring against bacterial, disposition per ED and/or discuss with ID/Ortho

**Surgical intervention indications:**

- Microbiologic testing for source samples
  - Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
  - For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained
- Microbiologic Testing for Source Samples
  - Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
- For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained

**Clinical suspicion for sepsis?**

Yes: Consider further imaging; Orthopedics to order MRIs from ED, advise on order for wards

No: Emergent orthopedic evaluation in ED

Yes: Emergency orthopedic consult either in ED or wards after ortho evaluation

While awaiting admission/Orthopedics to order MRIs from ED, advise on order for wards

**Does patient have septic knee?**

Yes: ED aspiration for synovial cell count, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5 years) and bacterial culture

No: Consider Lyme disease if travel to endemic area, send serologic studies from blood and consult ID/Ortho if needed

Does patient have suspected Septic knee?

Yes: ED aspiration for synovial cell count, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5 years) and bacterial culture

No: Consider Lyme disease if travel to endemic area, send serologic studies from blood and consult ID/Ortho if needed

**Microbiologic Testing for Source Samples:**

- Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
- For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained

**Surgical intervention indications:**

- Microbiologic testing for source samples
  - Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
- For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained

**Microbiologic Testing for Source Samples:**

- Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
- For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained

**Surgical intervention indications:**

- Microbiologic testing for source samples
  - Send aspirates or tissue samples (NO SWABS) for bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (children younger than 5), and pathology on all cases
- For joints, send synovial fluid for cell count, glucose, protein; send synovial tissue for pathology if obtained
Algorithm 2. Musculoskeletal Infection: Management

Patient diagnosed with acute musculoskeletal infection (MSK)

Yes

Are ANY of the following "SIGNS OF SEPSIS" TRUE:
- Systolic BP low for age
- New need for respiratory support
- Abnormal mental status
- Clinical or lab concerns for organ dysfunction

Yes

Are ONLY of the following TRUE:
- Source culture has been obtained
- Blood culture positive
- Multifocal infection
- Primary Team uncomfortable delaying antibiotics

No

Review plans to obtain source culture ASAP with Orthopedic Surgery and IR
- Wait to initiate antibiotic therapy until source culture obtained
- Serial clinical assessments by primary team

No

Have any of the following occurred during serial assessments?
- Source culture obtained
- Blood culture turns positive
- Clinical changes, patient ill appearing, organ dysfunction

Yes

Cover narrowly with IV antibiotic while following cultures and clinical response:
- Recommend cefazolin empirically (100% coverage of both MSSA and K. Virgul, cefazolin does not cover MRSA)
- Consider cefazolin + clindamycin if high suspicion for MRSA
- Consider cefazolin + vancomycin if septic arthritis of hip/shoulder AND drainage will be delayed
- If concerned for atypical bacterial source based on history or exposures, discuss empiric antibiotic choice with ID.
Narrow antibiotics based on microbiology testing (Table 1) and obtain source culture as soon as possible is not already obtained

No

If does not improve, consider:
- Redelte discussion with primary team, Ortho and ID
- Repeat laboratory assessment
- Repeat cultures
- Expand/change antibiotics
- Repeat imaging
- Repeat drainage
- Alternative diagnoses

No

Discharge planning for outpatient management:
- Patient has reached expected clinical improvement
- 
CRP/ESR normalized
- Minimum time on antibiotics
- Septic joint: 3 weeks, if patient less than 18 months, consider all septic joints contiguous osteomyelitis
- Osteomyelitis: 4 weeks
- Total length of therapy depends on severity as more severe/complicated infections will require longer therapy
- Home IV therapy via PICC line is rarely needed for MSK infections

Follow up:
- Follow weekly for clinical laboratory improvement
- Follow for antibiotic tolerance, compliance, and side effects
- Note: Children with MRSA osteomyelitis are at high risk for pathologic fracture

If See antibiotic choices, dosing and side effects in Table 1

Inclusion Criteria:
- Patients 6 months to 18 years
- Susicion of acute (less than 2 weeks) deep musculoskeletal infection (osteomyelitis, septic arthritis, pyomyositis)

Exclusion Criteria:
- Infants (less than 6 months)
- Post-op infection or foreign body
- Infections from penetrating trauma
- Medically complex children/Decubitus Ulcers
- Chronic infection
- CNS/Intracranial Infections
- Concern for necrotizing fasciitis

Pursue operative source control as soon as patient stability allows, particularly important for toxic shock

Treat intravenously until:
- Significant clinical improvement (weight bearing if allowed)
- Afebrile x 24 hours
- Known susceptibilities
- Falling CRP (check daily while on IV therapy)
- If blood cultures positive, repeat until negative x 48 hours
- If ongoing bacteremia, consider evaluation for intravascular infection or other foci
- Consider longer intravenous antibiotic course if inadequate drainage, unusual organism(s), hip joint involvement, multifocal, severe disease or persistent bacteremia.

* Clinicians cannot always identify early signs of organ dysfunction with physical examination alone. Consider obtaining CMP, lactate, and INR to complete evaluation for organ dysfunction if waiting to initiate antibiotics.
Algorithm 3. Musculoskeletal Infection: Orthopedic and Infectious Diseases Follow-up

**Inclusion Criteria:**
- Patients 6 months to 18 years
- Suspicion of acute (less than 2 weeks) deep musculoskeletal infection (osteomyelitis, septic arthritis, pyomyositis)

**Exclusion Criteria:**
- Infants (less than 6 months)
- Post-op infection or foreign bodies
- Infections from penetrating trauma
- Medically complex children/Decubitus Ulcers
- Chronic infection
- CNS/Intracranial Infections
- Concern for necrotizing fasciitis

**Infectious Diseases follow up:**
- Coordinate all ID follow up visits in conjunction with Ortho if possible
- Weekly labs to be drawn by PCP or at CHCO outpatient lab if possible
- ID will review results of weekly labs and adjust therapy if needed
- ID follow up after antibiotics completed only needed if ongoing infection concerns
TABLE OF CONTENTS

Algorithm 1. Musculoskeletal Infection: Diagnostic
Algorithm 2. Musculoskeletal Infection: Management
Algorithm 3. Orthopedic and Infectious Diseases Follow-up for MSK Infection
Clinical Assessment
Initial Evaluation and Labs
Initial Imaging Studies
Admission Criteria
Procedures | Interventions
Consultations to Consider
Initial Therapies | Emergency Department (ED) and Inpatient Unit
Microbiology Testing Process
Change to Oral Antibiotics | Discharge Criteria
Discharge Planning and Follow-up
Parent | Caregiver Education
Table 1. Antibiotics and Monitoring for Patients with MSK Infection
References
Clinical Improvement Team

TARGET POPULATION

Inclusion Criteria

- 6 months to 18 years
- Suspicion of acute (less than 2 weeks) deep musculoskeletal infection; osteomyelitis, septic arthritis, pyomyositis

Exclusion Criteria

- Postoperative infection or foreign bodies (including indwelling orthopedic hardware)
- Infections from penetrating trauma
- Chronic infection
- Infants (less than 6 months), as they may have: 1) other pathogens, 2) multifocal disease, and 3) poor oral antibiotic absorption
- Medically complex children (e.g. immunocompromised, significant neurologic deficits, decubitus/pressure ulcers, etc)
- CNS/Intracranial Infections
KEY TREATMENT PRINCIPLES

Indicated:
- Laboratory workup including complete blood count (CBC) with differential, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and blood cultures\(^1\)\(^-\)\(^7\)
- Radiographic imaging\(^1\), \(^2\), \(^5\), \(^7\)
- Source culture prior to antibiotics in well-appearing patients\(^1\), \(^2\), \(^5\), \(^6\), \(^8\)-\(^10\)

Not routinely indicated:
- Antibiotics prior to source culture for well-appearing children with negative blood cultures
- PICC/central line placement

CLINICAL ASSESSMENT

1. Vital signs on admission
2. Observation and/or history for:
   - Limited used or immobility of extremity or spine
   - Gait disturbance/Limp
   - Inability to bear weight
   - Pain
   - Fever greater than 38.5°C
   - Travel and exposures
   - Clinical signs of sepsis
3. Physical examination for the presence of:
   - Limited range of motion
   - Tenderness
   - Swelling
   - Warmth at site
   - Erythema
   - Psoas sign
   - Fever
   - Inadequate perfusion or organ dysfunction

INITIAL EVALUATION AND LABS

1. Complete blood count (CBC) with differential, C-reactive protein (CRP), Erythrocyte sedimentation rate (ESR), Blood culture x 2 (per Children’s Hospital Colorado protocol)
2. If patient is ill-appearing, obtain Lactate, CMP, and INR to evaluate for organ dysfunction per sepsis pathway\(^11\)-\(^13\)
3. If knee/elbow: Arthrocentesis, interpretation and disposition in ED. Arthrocentesis may be performed by ED or Orthopedics (if ED physician, consider Ortho consult prior to arthrocentesis)
CLINICAL PATHWAY

- If suspected bacterial (>50,000 WBC count, + Gram stain, +MRSA/SA SSTI PCR, or presentation clinically consistent), proceed with MSK Clinical Pathway\(^{14, 15}\)
- If travel/cell count supports, consider Lyme disease (send serology) and consult Orthopedics/Infectious Diseases if needed

4. Suspected deep-seated bone or joints (e.g. shoulder, hip): Obtain labs/imaging; consult Orthopedics

INITIAL IMAGING STUDIES

- **Plain radiographs (all patients):** Radiographs can be insensitive for the evaluation of acute soft tissue and osseous infection, as changes on x-ray are often a late finding with MSK infections. However, if infectious changes seen may avoid further imaging. Soft tissue swelling, though nonspecific, may be an early finding of MSK infection.\(^{5-7, 9, 16}\)

- **Ultrasound:** Hip and/or knee ultrasound may be helpful in the setting of equivocal physical exam findings for joint effusion. Consider ordering if a negative ultrasound would avoid further imaging and/or aspiration.\(^{1, 6, 7}\)

Additional Imaging as directed by ORTHOPEDIC CONSULTANT AND RADIOLOGY

- **MRI:** The orthopedic team is to place all MRI orders in EPIC from the ED. MRI should not be ordered until Orthopedics has evaluated patient. This is to assure the correct exam is ordered in the appropriate time frame.

MRI ordering process:

**Anschutz Medical Campus MRI Process**

Patients needing EMERGENT exam:

- 7am - 10pm: Call lead MRI tech directly (7-8648) to schedule a sedated or non-sedated exam.
- 10pm - 7am: If an MRI cannot wait for earliest sedated or non-sedated slot, please have Orthopedic attending call the CT tech (7-8645), who will call the on-call radiologist to approve calling in an MRI tech to perform an emergent exam. If exam will need sedation, please have Orthopedic attending call on-call anesthesiologist (7-8339) to coordinate.

Patients needing URGENT (not critical/emergent) exam:

- 7am - 10pm: Call lead MRI tech directly (7-8648) to schedule a sedated or non-sedated exam, goal is to perform MRI within 10 hours.
- After 10pm NON-SEDATED patient: Please have Orthopedic provider call CT Tech (7-8645), who will schedule and place patient in a 6:30am slot (Weekdays) or earliest slot available (Weekends/Holidays).
- After 10pm SEDATED patient: Please have Orthopedic provider call CT Tech (7-8645), who will schedule and place patient in a 7:30am slot (Weekdays) or the earliest sedated slot available (Weekends/Holidays).
  - Weekdays: Anesthesiology will accommodate sedated MRI add-on by sending swing shift anesthesiologist if necessary.
  - Weekends/Holidays: If sedated MRI is outside 10 hour goal, Orthopedic attending should call anesthesia to find first available anesthesiologist.

**Colorado Springs Hospital MRI Process**

Patients needing EMERGENT exam:

- 7am - 7pm: Call lead MRI tech directly (5-6350) to schedule a sedated or non-sedated exam.
- 7pm - 7am: If an MRI cannot wait for earliest sedated or non-sedated slot, please have Orthopedic attending call the CT tech (5-6360), who will call the on-call radiologist to approve calling in an MRI tech to perform an emergent exam. If exam will need sedation, please have Orthopedic attending call on-call anesthesiologist (5-6824) to coordinate.

Patients needing URGENT (not critical/emergent) exam:
7am - 7pm: Call lead MRI tech directly (5-6350) to schedule a sedated or non-sedated exam, goal is to perform MRI within 10 hours.

After 7pm & Holidays: Please have Orthopedic provider call CT Tech (5-6360), who will coordinate with on-call MRI tech and anesthesiology (if sedated exam) to schedule patient for the earliest available time.

ADMISSION CRITERIA

- Admit all patients with suspected and confirmed acute musculoskeletal infections unless indicated otherwise by Pediatric Orthopedics or ID.
- If a patient with suspected or confirmed MSK infection presents to South/North Campus ED and will require inpatient admission, please consult orthopedic surgery and infectious disease to review clinical scenario and discuss best location for patient admission. Efforts should be made to obtain MRI (if needed) at South/North Campus if this can be obtained without a delay in care.

PROCEDURES | INTERVENTIONS (Emergency Department/Operating Room/Interventional Radiology)

Recommend biopsy/aspiration to establish microbial etiology, for therapeutic benefit (to prevent rupture into contiguous joint, for example) and for abscess discovery. Send ASPIRATE of pus or fluid (NOT A SWAB) for Gram stain and bacterial culture, MRSA/SA SSTI PCR, Kingella kingae PCR (if patient < 5 yo), and tissue/synovium for pathology if possible. If joint fluid, send for bacterial culture, Gram stain, MRSA/SA SSTI, Kingella kingae PCR (if patient < 5 yo), cell count with differential, and fluid to hold. If unusual case or exposures, consult Infectious Diseases for further testing/culturing recommendations. (2, 5-7, 9, 17-19)

CONSULTATIONS TO CONSIDER

Seek primary attending’s approval prior to consulting specialist; primary team to coordinate consult communication.

Orthopedics

Orthopedics prefers to be consulted on all confirmed and probable musculoskeletal infections as soon as suspected, and prior to advanced imaging, as orthopedics can facilitate and will order timely MRI.

Infectious Disease

Infectious Diseases prefers to be consulted on all confirmed and probable musculoskeletal infections as soon as suspected, particularly if ID to follow as an outpatient or upon unit transfer.

Rheumatology

- Polyarthritis
- Suspicion or history of juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), rheumatic fever, post-strep arthritis or psoriasis
- Chronic joint effusion

INITIAL THERAPIES | EMERGENCY DEPARTMENT AND INPATIENT UNIT

1. Pain control administered per Emergency Department/primary team.

2. Source culture should be obtained prior to starting antibiotics (unless blood culture positive, multifocal infection, patient ill-appearing, lab findings of end organ dysfunction, or clinical concern for sepsis). Goal is source culture by end of day after admission in orthopedic surgery room if needed. (1, 2, 5, 6, 8-10)
3. **Patients without signs of sepsis**: Cover narrowly with IV agent while following cultures and clinical response. If concerned for atypical bacterial source based on history or exposures, discuss empiric antibiotic choice with ID.
   - **Recommend cefazolin empirically** (100% coverage of both MSSA and K. kingae). (2, 18, 20-23)
   - Consider cefazolin + clindamycin if high suspicion for MRSA (prior history of MRSA infection, family history, etc.). Per internal data for MSK infections from 2014-2018, 81% of identified pathogens are S. aureus, the majority of which are MSSA (86%). Clindamycin resistance was seen in 16% of MSSA isolates and 7% of MRSA isolates from patients with MSK infections.
   - If patient has septic arthritis of hip or shoulder AND drainage will be delayed >12 hours, consider cefazolin + vancomycin for empiric MRSA coverage while cultures/PCR testing pending.

4. **Patients with clinical concern for sepsis**: Do not delay antimicrobials, cover broadly immediately with IV agent after obtaining blood cultures.
   - **Recommend ceftaroline empirically** (broad coverage for MSSA, MRSA, and Gram negative coverage)(24-26)
   - Consider adding clindamycin if limited source control or concern for toxin-mediated illness such as toxic shock syndrome(27-31)

5. Narrow antibiotics based on microbiology testing as follows:
   - Once bacterial species is identified by rapid diagnostics or culture, but final susceptibilities pending
     - MSSA or K. kingae: Cefazolin (covers 100% of MSSA and K. kingae)(23)
     - MRSA: Ceftaroline until clindamycin susceptibility/resistance known.
       - Alternative MRSA IV antibiotics include vancomycin and daptomycin (do not use daptomycin if concern for lung infection).
     - *Streptococcus pyogenes*: Cefazolin or ampicillin (both cover 100% S. pyogenes)(23)
   - Once final susceptibilities available:
     - MSSA: Cefazolin or clindamycin if susceptible
     - MRSA-Clindamycin Susceptible: Can transition to clindamycin pending clinical improvement after discussion with ID.
     - MRSA-Clindamycin Resistant: Options include ceftaroline, vancomycin, daptomycin, linezolid, and trimethoprim-sulfamethoxazole among others. Decision for MRSA antimicrobial should be made in consultation with ID.

6. Additional information on antibiotics, dosing, and monitoring is available in Table 1.

**Microbiology Testing Process**

Identifying a bacterial etiology allows for targeted antimicrobial therapy that is both more effective and less likely to cause avoidable adverse events. (2, 9, 10)

**Specimen types**

Recommend obtaining two blood cultures on admission (per CHCO protocol). Unless likely bacterial source already identified via blood culture, recommend obtaining source samples from infected area(s), such as aspirates or tissue biopsies of bone, synovial fluid, and abscesses/fluid collections. Among MSK infections at CHCO from 2014-2018, 75% of MSK patients had a pathogen identified (24% blood culture, 28% source culture, 23% both). Identifying the causative bacterial pathogen decreases broad spectrum antibiotic exposure leading to fewer adverse events, decreased days of therapy, decreased PICC line placement, and improved outcomes with simplified management decisions. (8, 32)
Microbiologic Testing Process

Blood Cultures: Once bacterial growth in incubated blood cultures bottles is sufficient, Biofire® FilmArray® Blood Culture Identification (BCID) is performed. BCID is a multiplex PCR and includes targets for pathogens commonly found in MSK infections (MSSA, MRSA, Group A Streptococcus pyogenes, Streptococcus pneumoniae, etc). Turn-around time for BCID results is ~90 minutes from time of bacterial growth in specimen sample. For patients with Staphylococcus aureus identified via blood culture at CHCO, median time to blood culture growth is 19 hours. Final bacterial culture results and antimicrobial susceptibilities are typically completed 2-3 days after collection.(33, 34)

Source Cultures: Recommend bacterial cultures for all source specimens. Aspirates of source samples can also be inoculated into standard blood culture bottles for “broth-enriched” cultures. If sufficient bacterial growth is reached on broth-enriched source cultures, BCID testing can be performed to identify the same targets as blood culture specimens. Yield from fungal and mycobacterial cultures from MSK source specimens is very low. No fungal/mycobacterial culture at CHCO between 2014-2018 identified a causative pathogen from any patient with acute MSK infections. Fungal and mycobacterial cultures from MSK sources should not routinely be sent unless high suspicion based on clinical and exposure history. Rapid diagnostic testing is also available directly on source specimens as described below and may be performed immediately after source specimen collection, they do not need to be incubated prior to testing. Rapid diagnostic testing for source samples includes:

- MRS/SA SSTI PCR (Cepheid®): Rapid direct-from-source testing to identify MSSA or MRSA from bone, joint, or deep abscess samples. Turn-around time of ~90 minutes from time of sample receipt in lab. (14, 15)
- Kingella kingae PCR: Recommended for patients < 5 yo. Rapid direct-from-source testing to identify Kingella kingae from bone, joint, or deep abscess samples. Turn-around time <24 hours from time of sample collection. (14, 17, 18)

Note: For both BCID and MRS/SA SSTI PCR, if Staphylococcus aureus is identified but MRSA is not identified, recommend targeting antimicrobial therapy for presumptive MSSA infection as described in Table 1 while bacterial culture results pending.

CHANGE TO ORAL ANTIBIOTICS | DISCHARGE CRITERIA

- Treat intravenously and inpatient until: (2, 7, 35-43)
  - Clinically substantially improved (weight bearing if allowed, improved motion of infected joint, well-appearing)
  - Afebrile x 24 hours
  - Known susceptibilities identify an effective oral antimicrobial
  - Falling CRP

- If blood cultures positive, repeat daily after initiation of antibiotics until negative x 48 hours; if persistent bacteremia, consider evaluation for intravascular infection (e.g. septic thrombophlebitis adjacent to MSK infection or infective endocarditis) and/or other infectious foci and treat with longer course of intravenous antibiotics.(44)

- If patient develops respiratory symptoms (chest pain, cough, shortness of breath, hypoxia), recommend evaluation for septic pulmonary emboli due to intravascular infection (e.g. septic thrombophlebitis adjacent to MSK infection or infective endocarditis).

- Also consider longer course of intravenous treatment if: adequate drainage not achieved, unusual organism(s), hip joint involvement, multifocal disease, unusually severe disease, concern for poor oral absorption or adherence.
If condition does not improve, consider:
- Bedside discussion with Primary Team, Orthopedic Surgery, and Infectious Diseases to re-evaluate plan
- Repeat laboratory assessment
- Repeat cultures
- Expand/change antibiotics
- Repeat imaging \(^{(45)}\)
- Repeat drainage
- Alternate diagnoses

**DISCHARGE PLANNING AND FOLLOW-UP**

1. Assure family understands importance of compliance, can purchase medications, and understands possible side effects of antibiotics *(Table 1)*. Arrange home IV therapy if indicated, though rarely is home IV therapy required for MSK infections.

2. Treat until:
   - Patient has reached expected clinical improvement for condition
   - ESR/CRP normal
   - **Minimum** total time on antibiotics: \(^{(37, 39-41, 46)}\)
     - Septic joint: 3 weeks; if less than 18 months, consider all septic joints contiguous osteomyelitis
     - Osteomyelitis: 4 weeks
     - Length of therapy depends on severity, and some infections will require longer therapy

3. Infectious diseases or primary care follow up; coordinate ID follow up visits with Ortho if possible *(Algorithm 3)*
   - Follow each 1-2 weeks as needed for:
     - Continued clinical improvement
     - Antibiotic tolerance/compliance
     - Improving ESR/CRP
     - Laboratory indications of antibiotic side effects *(obtain baseline and follow up labs per Table 1)*

4. Orthopedic follow up *(Algorithm 3)*
   - Surgical patients and those with joint involvement should follow up at two weeks post operatively, all other patients should follow up at 4-6 weeks with option for imaging
   - Obtain baseline plain radiograph at three months
   - Remaining follow up after three months will be determined at discretion of orthopedics
   - Note children with MRSA osteomyelitis are at high risk for pathologic fracture, children with hip infection are at risk for avascular necrosis \(^{(47)}\)

**PARENT | CAREGIVER EDUCATION**

It is suggested that parent/caregiver education contain the following information:

- Education on obtaining and taking antibiotics
- Pain control measures
- Return precautions and contact information for orthopedics and infectious diseases
- Education regarding antibiotic side effects
- PICC line training and education (including risk of infection) if applicable
TABLE 1. Antibiotics and Monitoring for Patients with Musculoskeletal Infections  
(Other antibiotics may be indicated based on culture results)

### Intravenous Antimicrobials

<table>
<thead>
<tr>
<th>Daily Amount</th>
<th>Cefazolin</th>
<th>Clindamycin a</th>
<th>Ampicillin</th>
<th>Ceftriaxone</th>
<th>Ceftaroline b</th>
<th>Vancomycin c</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHCO Total Daily Maximum Dosing for MSK Infection</td>
<td>6000 mg divided Q8H a</td>
<td>2700 mg divided Q8H</td>
<td>8000 mg divided Q6H</td>
<td>2000 mg Q24H</td>
<td>1800 mg divided Q8H</td>
<td>6000 mg divided Q8H</td>
</tr>
</tbody>
</table>

### Oral Antimicrobials

(Once patient has met criteria for transition to oral antimicrobial therapy, see Algorithm 2)

<table>
<thead>
<tr>
<th>Daily amount</th>
<th>Cefalexin</th>
<th>Clindamycin a</th>
<th>Amoxicillin</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHCO Total Daily Maximum Dosing for MSK Infection</td>
<td>4000 mg divided QID</td>
<td>1800 mg divided TID</td>
<td>3000 mg divided TID</td>
</tr>
</tbody>
</table>

### Organism

- **MSSA**: + /- a  
- **MRSA**: + /- a  
- **S. pyogenes (Group A strep)**: + /-  
- **S. pneumoniae**: + /-  
- **Kingella kingae g**: + /-  

### Labs

- **Monitor for infection resolution and side effects**: CBC w/diff, CRP or ESR, BUN, Cr h  
- **Additional labs**: urinalysis to screen for interstitial nephritis. Clinically, patients should be followed for signs of allergy such as rash, diarrhea (any antibiotic can cause *Clostridioides difficile* colitis), fevers (severe allergy, line infection, recurrent infection), compliance, and other complaints. All antibiotics can cause anaphylaxis. Side effects listed are most common and do not represent all side effects.

### Notes:

- a Oral bioavailability for clindamycin is >90%. The use of clindamycin for MRSA depends on local susceptibility patterns and susceptibility testing (if available). It is important that the microbiology lab perform a “D-test” or equivalent for inducible clindamycin resistance. At Children’s Hospital Colorado, D-test is routinely performed, and among MSK patients 16% of MSSA and 7% of MRSA isolates are resistant to clindamycin. If patient is <5 years, clindamycin does not routinely cover *K. kingae*.  
- b Consultation with ID strongly encouraged prior to initiating ceftaroline for any non-critically ill patient.  
- c Vancomycin can be given by continuous infusion; discuss with pharmacy. Adjust dose with levels.  
- d For severe cases, may use cefazolin 8000mg divided Q6H.  
- e For severe cases, may use ampicillin 12000mg divided Q4H.  
- f While ceftriaxone has activity against MSSA, anti-staphylococcal penicillins (such as nafcillin) or first generation cephalosporins (such as cefazolin) are preferred therapy.  
- g Kingella kingae can cause bone and joint infection in patients from 6 months to 5 years of age but is difficult to culture. PCR-based testing can increase yield for *K. kingae* identification. *K. kingae* predominantly causes septic arthritis but can also cause isolated osteomyelitis and tenosynovitis; it generally has a milder presentation than *S. aureus*. Unless microbial cause is known, *K. kingae* should be empirically covered in children <5 years.  
- h All patients on antibiotics for MSK infection should be followed with a weekly CBC with differential, CRP or ESR, and BUN/Cr. There are additional labs specific to the antibiotic, for example: urinalysis to screen for interstitial nephritis. Clinically, patients should be followed for signs of allergy such as rash, diarrhea (any antibiotic can cause *Clostridioides difficile* colitis), fevers (severe allergy, line infection, recurrent infection), compliance, and other complaints. All antibiotics can cause anaphylaxis. Side effects listed are most common and do not represent all side effects.

Please consult ID for additional antimicrobial options such as daptomycin, doxycycline, trimethoprim-sulfamethoxazole, or linezolid.
REFERENCES


Clinical pathways and algorithms are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways and algorithms are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. The information presented should not be relied upon as being comprehensive or error-free. Furthermore, this document and the information it contains may not be distributed externally or reproduced for external distribution in any form without express written permission of Children’s Hospital Colorado. The information presented is provided for use solely at your own risk on an “as-is” basis. Any person or entity reviewing this document and the information it contains should conduct their own review of the specified topic(s) and customize the information to meet their specific needs. Neither Children’s Hospital Colorado, Pediatric Care Network, or any other Children’s Hospital entities accepts any liability for the content, or for the consequences of any actions taken on the basis of the information provided. Children’s Colorado and the Pediatric Care Network declare no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.
Discrimination is Against the Law. Children’s Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children’s Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children’s Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children’s Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720-777-9800.

If you believe that Children’s Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 10th Avenue, B450, Aurora, Colorado 80045, Phone: 720 777 1234, Fax: 720 777 7257, corporate.compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at: [corporate.hhs.gov/ocr/complaints], or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201-2500, 800-368-1019 (TDD) Complaint forms are available at: www.hhs.gov/ocr/office/file/index.html.

Children’s Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, báne a su disposición servicios gratuitos de asistencia lingüística. LLame al 1-720-777-9800.


注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

МУЮНУУ: Эрээн зөрчилдөөсөөгөн буюл, би таныздагы туура хувь алуу үчүн 1-720-777-9800 мактанмаса болсо, куршумдуу суроо жооп өтөөчү.


 culpaquiin bii hokhukos qinjaa naluqos qujuri yapatcha, muriqaj, kuchumi, dala. ¡Ofrezcemos ayuda gratuita! 1-720-777-9800.


注意事項: 日本語を話される場合, 無料の言語支援をご利用いただけます。1-720-777-9800 まで、お電話にてご連絡ください。

Nǐ Or bu ru na asu lbo, asusu aka osus n'ifu, delu, aka. Call 1-720-777-9800.